Curanex Pharmaceuticals Inc
CURX
$4.20
-$0.84-16.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 14.96% | -2.17% | |||
| Gross Profit | -14.96% | 2.17% | |||
| SG&A Expenses | -21.07% | 17.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.47% | 2.94% | |||
| Operating Income | -4.47% | -2.94% | |||
| Income Before Tax | -4.47% | -2.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.47% | -2.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.47% | -2.51% | |||
| EBIT | -4.47% | -2.94% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -4.40% | -2.61% | |||
| Normalized Basic EPS | -4.39% | -2.61% | |||
| EPS Diluted | -4.40% | -2.61% | |||
| Normalized Diluted EPS | -4.39% | -2.61% | |||
| Average Basic Shares Outstanding | 0.07% | -0.10% | |||
| Average Diluted Shares Outstanding | 0.07% | -0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||